Northwestern University researchers reported heterobifunctional proteomimetic polymers (HYDRACs) that selectively bind and target intrinsically disordered oncogenic drivers MYC and KRAS for cellular degradation. The polymers co‑display target‑recognizing peptides and degron motifs to recruit intracellular quality‑control machinery, yielding target depletion across cancer cell lines and tumor growth inhibition in mice. The approach circumvents the need for traditional small‑molecule pockets and offers a modular polymer chemistry path to degrade previously refractory proteins. Authors presented cell culture and in vivo proof‑of‑concept, highlighting tumor accumulation and antiproliferative effects. For drug discovery, HYDRACs illustrate a chemistry‑forward route to engage disordered or shallow‑pocket targets and expand the degradable proteome beyond E3‑ligase‑based small‑molecule degraders.